Nur Ink: What the DCC Agreement Is Really Worth, and Who Captures the Value If It Works
In the main article, DCC was the strongest commercial headline. The narrower question here is how roughly $12 million of minimum purchases, a 700,000-liter commitment, royalties, and an option for up to 20% of the distribution company actually split across value layers, and how much of that is truly accessible to Nur shareholders.
In the main article, the core conclusion was that DCC is the most important commercial door that has opened for Nur Ink, but not yet proof of a repeatable sales run-rate. This continuation isolates the economics of that agreement: what is actually hard inside it, what value already sits with Nur, and what remains an option on the success of a distribution vehicle Nur does not control.
Four points need to be clear upfront:
- The DCC headline bundles several different value layers. There is ink supply, territorial exclusivity, royalties, and an equity option in the distribution company.
- The filings describe the floor in two different units. In the annual-report note, exclusivity is tied to annual minimum purchases at agreed tariffs totaling about $12 million through the end of 2028. In the court filing tied to the warrant extension, the company already described the binding agreement as a 3-year commitment with a 700,000-liter minimum.
- The value to Nur is not cumulative. As long as Nur does not exercise the distribution-company warrants, it is entitled to royalties and DCC funds the distribution company on its own. If Nur exercises and reaches up to roughly 20% ownership, the royalties stop and the parties begin funding the activity jointly.
- So even if DCC works, not all of the value stays with Nur. Some of it remains at the distribution-company level, and some of it may first show up through Nur’s own share price and warrant-exercise dynamics.
What Is Actually Hard, and What Is Still Conditional
The DCC agreement sounds large because it is not presented as a plain distribution contract. In the October 2025 memorandum of understanding, the company tied exclusivity to annual purchase targets in 2026 through 2028, at tariffs agreed between the parties, for an aggregate amount of about $12 million. In February 2026 the full agreement was signed with DCC’s dedicated Americas distribution vehicle, and in the warrant-extension court filing the company already described the binding agreement as a 3-year deal with a minimum commitment to purchase 700,000 liters of ink, alongside a first commercial order.
The important point is that this headline is not the same thing as guaranteed revenue to Nur. The note says the minimum quantities are tied to agreed tariffs, but it does not disclose the tariff table itself, the royalty rates, or the internal economics of the distribution company. That means the roughly $12 million cannot be translated automatically into Nur revenue, gross profit, or cash flow. This is not a footnote. It is central to understanding the contract.
The second point is that exclusivity matters, but it is not absolute. First, it does not apply to certain excluded manufacturers named in the memorandum. Second, Nur may end exclusivity if DCC fails to meet the annual minimum purchase targets. Third, DCC itself may terminate exclusivity on 60 days’ notice. So the agreement opens a strong channel, but it does not create a rigid three-year stream that is already locked and monetized.
At the same time, there is also a real anchor that separates this agreement from a memorandum or a loose commercial statement. When the full agreement was signed on February 16, 2026, a first order was placed, and the company also said the distribution company would transfer a first payment on account of that order. That is the detail that moves DCC out of the “maybe” bucket and into the “there is an initial commercial start” bucket. It is simply not enough yet to settle what the eventual run-rate will be.
| Layer in the agreement | What is actually disclosed | Who benefits first | What is still missing for proper valuation |
|---|---|---|---|
| Ink supply | Annual purchase targets, about $12 million through end-2028, and a 700,000-liter minimum over 3 years | Nur as the ink supplier | Full pricing, actual order cadence, and gross margins |
| Americas exclusivity | North, Central, and South America, subject to minimum quantities and excluding certain manufacturers | DCC and the distribution vehicle in the channel layer | How broad the carve-outs are and how durable exclusivity will prove |
| Royalties | Set in the memorandum, but the rate itself is not disclosed | Nur, as long as the distribution-company warrants are not exercised | The royalty rate and the sales base it applies to |
| Equity option | Warrants exercisable without consideration for up to roughly 20% of the distribution company | Nur as an option holder on distributor-level success | Whether it is economically worth giving up royalties and starting to co-fund the vehicle |
This Is Not One Contract, but Two Deals Stacked Together
What is really interesting in DCC is that Nur did not sign only a supply agreement. It also built an option on the distribution layer itself. Before exercising the distribution-company warrants, Nur remains primarily the ink manufacturer and the owner of the intellectual property. It supplies ink, remains entitled to royalties on sales through the distribution company, and DCC funds the distribution company on its own. That is a relatively convenient structure for Nur: a commercial channel without having to finance that distribution arm upfront.
But once Nur chooses to move into the equity layer and exercise the warrants, the economics shift. Nur can reach roughly 20% ownership in the distribution company without paying consideration for the exercise itself, but from that point it stops being entitled to royalties from that vehicle and the parties are supposed to fund the activity jointly. So royalties and equity ownership cannot be counted as if they were two separate upside buckets that will simply stack on top of one another.
That is a subtle but critical point. Nur’s warrants in the distribution company are not an option on the full economics of the Americas channel. They are an option on a minority stake of up to 20% in the distributor layer, and the price of moving into that layer is giving up future royalties and accepting part of the funding burden. So when asking what DCC is worth, the reader has to separate accessible value from conditional value.
The more accessible value is the ink-supply layer, the first order, and the royalties while they remain in force. The more conditional value is the equity stake, because exercising into that layer only becomes rational if the distributor’s economics are strong enough to justify giving up royalties and taking on funding obligations.
Who Actually Captures the Value If the Channel Works
This may sound abstract, but it matters a lot. If DCC works well, there are several layers of beneficiaries.
At the first level, Nur benefits as the ink supplier. This is the cleanest part. If repeat orders begin to arrive, the ink itself moves through Nur, and the company benefits from the product it owns both commercially and intellectually. As long as the distribution-company warrants have not been exercised, Nur also has a royalty layer tied to sales through that vehicle. This is the part closest to Nur’s own income statement, even if the exact figures have not yet been disclosed.
At the second level, a large part of the channel value is built inside the distribution company itself. That is where the market access, local distribution, and Americas commercial platform sit. As long as DCC funds that arm on its own, Nur benefits from it indirectly, but does not own its full economics. Even after full warrant exercise Nur would hold only up to 20%. So if this channel turns into a very strong distributor, most of the distributor-level value still remains on the other side, not inside Nur.
At the third level sit Nur’s own shareholders and holders of Nur’s listed warrants. Here the court filing for the Series 1 extension gives an important clue. The company itself used the DCC agreement, together with the first order and other product progress, to argue that these developments could positively affect the company and its valuation and increase the incentive to exercise Nur’s own warrants. In other words, the company itself is saying that the first visible value from DCC may appear through market value and capital-structure instruments, not necessarily immediately through recognized revenue.
That is a point many readers miss. DCC can be a big event even if reported revenue rises only gradually. If the market becomes convinced that the Americas channel is real, part of the value may pass first through a higher share price and better warrant-exercise economics for Nur. But that also means that, in the early stage, part of the value can be trapped in the capital structure before it is fully visible in the operating accounts.
What Has to Happen for the Value to Move from the Headline into the Accounts
The first test is very clear: the first order has to turn into cadence. As long as the evidence consists only of a first order and of a first payment that is supposed to be made on account of that order, DCC is an open channel, but not yet a proven engine. What matters is not only that minimum quantities exist on paper, but whether actual progress toward those quantities begins to show up.
The second test is disclosure. The company already discloses the architecture of the agreement, but not the royalty rates, not the full ink pricing, and not the economics of the distribution company. So at this stage the reader can understand who is supposed to benefit, but still cannot calculate what each layer is actually worth. For the market, that is an important gap. Without those numbers, DCC remains mainly a promising economic framework, not a fully modeled profit engine.
The third test is path choice. If Nur stays for a long time in the model of ink supply plus royalties, it is choosing the easier cash model. If it chooses to exercise the warrants and become an equity partner of up to 20% in the distribution company, it is betting on higher value inside the distributor layer itself, but also replacing royalties with a minority equity stake and a share of funding needs. That is not the same economics.
The fourth test is the durability of exclusivity. As long as DCC meets the minimum quantities, exclusivity across the Americas is an important asset. If not, Nur can end it. At the same time, DCC can also terminate exclusivity on 60 days’ notice. So what looks today like an important commercial entry gate still has to pass a durability test, not just a signing test.
Conclusion
The DCC agreement is worth more than a plain distribution contract because it concentrates four layers that do not usually arrive together: a purchase floor, territorial exclusivity, royalties, and an equity option in the distribution company. But for exactly that reason it is also easy to count the same upside twice.
The more conservative and more correct reading is this: the cleanest value to Nur right now is ink supply plus royalties, while DCC funds the distribution company on its own. The option for up to 20% of that distributor can be worth a lot, but only if the Americas channel proves strong enough to justify giving up royalties and sharing the funding burden.
So if DCC works, Nur clearly participates in the value, but it does not capture all of it. Some of the value remains in the distribution company and with its shareholders, and some of it may first travel through Nur’s market value and warrant-exercise dynamics. In that sense, DCC is not only a test of demand for Nur’s ink. It is a test of value capture: how much of the success will really stay with Nur, at which layer, and at what price.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.